---

# Laboratory Corporation of America Holdings (Labcorp) (LH) Investment Report - Fiscal 2021 Q3

---

## 1. Financial Analysis

### Key Highlights
- Labcorp raised its full-year guidance for revenue, adjusted EPS, and free cash flow due to strong Q3 performance.
- The Base Business for both Diagnostics and Drug Development exhibited significant growth, with 10% and 22% increases respectively.
- Strategic M&A activities and innovations, including new diagnostic offerings, have strengthened Labcorp's market position.

### Key Financial Metrics

| Metric                    | Current Quarter | Previous Quarter | QoQ Change | Previous Year | YoY Change |
|---------------------------|-----------------|------------------|------------|---------------|------------|
| Revenue                   | $4.06 billion   | $3.84 billion    | 5.8%       | $3.90 billion | 4.3%       |
| Earnings per Share (EPS)  | $6.82           | $6.13            | 11.3%      | $8.41         | -18.9%     |
| Gross Profit              | $1.39 billion   | $1.26 billion    | 10.0%      | $1.56 billion | -11.2%     |
| Operating Income          | $767 million    | $704 million     | 8.9%       | $1.05 billion | -26.7%     |
| Net Income                | $587 million    | $467 million     | 25.7%      | $703 million  | -16.5%     |
| Operating Cash Flow       | $767 million    | $487 million     | 57.5%      | $786 million  | -2.4%      |
| Capex                     | $118 million    | $97 million      | 21.3%      | $77 million   | 53.2%      |
| Short-term Debt           | $401 million    | $403 million     | -0.5%      | $779 million  | -48.5%     |
| Long-term Debt            | $5.42 billion   | $5.42 billion    | 0.0%       | $5.42 billion | 0.0%       |
| Cash & Cash Equivalents   | $2.04 billion   | $1.96 billion    | 4.1%       | $667 million  | 205.5%     |

### Key Financial Ratios and Investment Insights

| Metric                | Current Quarter | Previous Quarter | Previous Year | Formula   | Interpretation |
| --------------------- | --------------- | ---------------- | ------------- | --------- | -------------- |
| Gross Margin (%)      | 34.1            | 32.93            | 40.02         |           | Gross margin decreased YoY due to lower COVID testing |
| Operating Margin (%)  | 18.88           | 18.33            | 26.88         |           | Operating margin decreased YoY due to higher personnel costs and reduced COVID testing |
| Net Margin (%)        | 14.46           | 12.17            | 18.05         |           | Net margin decreased YoY reflecting similar pressures as operating margin |
| EPS Surprise (%)      | 38.62           | 10.85            | 58.38         |           | Positive EPS surprise indicating better-than-expected performance |
| Free Cash Flow        | $650 million    | $390 million     | $709 million  |           | Decrease in YoY free cash flow due to lower cash earnings |
| Capex / OCF (%)       | 15.35           | 19.95            | 9.82          |           | Increase in Capex as a percentage of OCF reflects strategic investments |
| Cash Conversion Ratio | 1.3065          | 1.0424           | 1.1177        |           | Improved efficiency in converting revenue into cash |
| Net Debt              | $3.78 billion   | $3.86 billion    | $5.53 billion |           | Decreasing net debt indicates strong cash management |
| Current Ratio         | 2.0844          | 2.1347           | 1.3574        |           | Healthy current ratio indicating strong liquidity position |
| Debt-to-Equity        | 0.5528          | 0.5687           | 0.7521        |           | Strong capital structure with lower leverage compared to last year |

### Concluding Summary

Labcorp's Q3 performance demonstrates continued resilience and strategic growth, with positive momentum in its Base Business and strategic M&A enhancing its market position. Despite reductions in COVID testing, the company's financial health remains robust, supported by strong cash flows and prudent capital management.

---

## 2. Market Analysis

### Opening Remarks Summary:
> "At Labcorp, we continue to leverage innovation, science, and technology to accelerate our strategy as we work to improve health and improve lives around the world. We delivered strong results this quarter and are raising full year guidance for revenue, adjusted EPS, and free cash flow."

| Theme              | Key Message Summary                                          |
|--------------------|--------------------------------------------------------------|
| Strategy / Vision  | Continued focus on innovation and leveraging technology      |
| Market Outlook     | Positive outlook with raised full year guidance              |
| AI / Innovation    | Notable advancements including an at-home COVID and flu kit  |

### Market Position & Trends:

#### Competitive Landscape

| Competitor   | Mentioned? | Strategic Position | Commentary            |
|--------------|------------|--------------------|-----------------------|
| N/A          | No         | N/A                | N/A                   |

#### Industry & Regulatory Trends

| Trend               | Impact              | Impact Summary         |
|---------------------|---------------------|------------------------|
| COVID Testing Demand| Mixed               | Decreasing COVID testing volume but preparedness for fluctuations |

**Impact Legend:**
- Positive: Beneficial effect on company performance
- Negative: Adverse effect on company performance
- Mixed: Both positive and negative effects
- Neutral: No significant impact

#### Growth Opportunities & M&A

| Opportunity   | Description                       | Timing / Likelihood     |
|---------------|-----------------------------------|-------------------------|
| M&A Pipeline  | Robust pipeline for acquisitions  | High likelihood         |

#### Customer Segments

| Segment Name  | Performance Summary               |
|---------------|-----------------------------------|
| Diagnostics   | Strong growth with 10% increase   |

### News Sentiment:

No relevant news articles found for LH in the 30 days prior to the earnings report on 2021-10-28.

---

## 3. Risk Assessment

| Risk Category         | Description                        | Likelihood | Impact (1â€“5) | Supporting Evidence                |
|----------------------|------------------------------------|------------|--------------|------------------------------------|
| Labor Market Tightness| Difficulty in retaining and hiring | Medium     | 4            | High personnel costs and labor inflation pressures discussed |

**Impact Level Scale:**
- **1** = Very Low (Minimal effect)
- **2** = Low (Minor impact on performance)
- **3** = Moderate (May affect segment or short-term earnings)
- **4** = High (Significant impact on operations or financials)
- **5** = Critical (Severe or existential threat)

**Likelihood:**
- **Low** = Unlikely under current conditions
- **Medium** = Reasonably possible
- **High** = Likely or already emerging

---

## 4. Investment Recommendation

- **Key Investment Drivers**: Strong recovery in the Base Business, robust M&A pipeline, and strategic focus on technology and innovation.
- **Major Risks**: Labor market tightness, variability in COVID-19 testing demand.
- **Recommendation**:
  - **Next Day**: Hold; observe market reaction to updated guidance and strategic initiatives.
  - **Next Week**: Buy; as synergy realization and backlog conversion strengthen performance outlook.
  - **Next Month**: Buy; continued growth in diagnostics and drug development anticipated.
- **Catalysts**: Strategic acquisitions, new product innovations, and updates on the company's structural review.

---

This report provides an overview of Labcorp's financial and market performance, identifies key risks, and offers investment recommendations based on current data and trends.